In vitro diagnostics introduces new technologies, sequencing methods, novel software algorithms, and multi-omics approaches to realise the goal of personalized medicine. Next-generation diagnostics has been the backbone of COVID-19-related emergency diagnosis, with an estimated 25% to 30% of revenue during 2020 and early 2021 related to this testing.
With the arrival of blood-based assays for chronic disease screening and next-generation molecular and point-of-care diagnostics for COVID-19-related testing, the global market grew 15.5% in 2021. Digital health solutions (patient portal + mobile app) facilitate a dramatic shift in care delivery from traditional to alternative sites, simplifying accessibility of diagnostic tests, and delivering an automated testing experience for labs to ensure rapid scalability. Patients have greater access control/faster turnaround time to results; providers can triage patients quickly through an efficient and connected workflow.
GROWTH PIPELINE DIALOG™
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.